<DOC>
	<DOCNO>NCT00347529</DOCNO>
	<brief_summary>The purpose study evaluate well vaccine tolerate site administration give , effect may subject ' wellbeing whether produce antibody responses body may protect subject catch pandemic strain flu</brief_summary>
	<brief_title>Safety Study Influenza Vaccine Against Potential Pandemic Strain Flu</brief_title>
	<detailed_description>Pandemic influenza occur strain influenza human population expose develops ability infect man spread person person . Some pandemic severe health impact widespread . This study evaluate PowderMed 's Particle Mediated Epidermal Delivery ( PMED ) DNA vaccine pandemic influenza potential alternative vaccine technology . This study represent first study vaccine provisionally assess safety immunogenicity ( ability generate immune response ) four different dose combination . The vaccine give prime-boost regimen vaccination Days 0 28</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adult volunteer ( woman must nonchildbearing potential ) Provided write informed consent No significant concomitant illness No allergy gold No immunosuppression due disease treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>DNA vaccine , influenza , immunogenicity , tolerability , PMED , pandemic</keyword>
</DOC>